Skip to main navigation Skip to search Skip to main content

High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers

  • Grace Banik
  • , Courtney B. Betts
  • , Shannon M. Liudahl
  • , Shamilene Sivagnanam
  • , Rie Kawashima
  • , Tiziana Cotechini
  • , William Larson
  • , Jeremy Goecks
  • , Sara I. Pai
  • , Daniel R. Clayburgh
  • , Takahiro Tsujikawa
  • , Lisa M. Coussens

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Biomarker assessments of tumor specimens is widely used in cancer research to audit tumor cell intrinsic as well as tumor cell extrinsic features including the diversity of immune, stromal, and mesenchymal cells. To comprehensively and quantitatively audit the tumor-immune microenvironment (TiME), we developed a novel multiplex immunohistochemistry (mIHC) platform and computational image processing workflow using a single formalin-fixed paraffin-embedded (FFPE) tissue section. Herein, we validated this platform using nine matched primary newly diagnosed and recurrent head and neck squamous cell carcinoma (HNSCC) sections sequentially subjected to immunodetection with a panel of 29 antibodies identifying malignant tumor cells, and 17 distinct leukocyte lineages and their functional states. Image cytometric analysis was applied to interpret chromogenic signals from digitally scanned and coregistered light microscopy-based images enabling identification and quantification of individual tumor cells, structural features, immune cell phenotypes and their functional state. In agreement with our previous study via a 12-plex imaging mIHC platform, myeloid-inflamed status in newly diagnosed primary tumors associated with significantly short progression free survival, independent of lymphoid-inflamed status. Spatial distribution of tumor and immune cell lineages in TiME was also examined and revealed statistically significant CD8+ T cell exclusion from tumor nests, whereas regulatory T cells and myeloid cells, when present in close proximity to tumor cells, highly associated with rapid cancer recurrence. These findings indicate presence of differential immune-spatial profiles in newly diagnosed and recurrent HNSCC, and establish the robustness of the 29-plex mIHC platform and associated analytics for quantitative analysis of single tissue sections revealing longitudinal TiME changes.

Original languageEnglish (US)
Title of host publicationTumor Immunology and Immunotherapy - Integrated Methods Part A
EditorsLorenzo Galluzzi, Nils-Petter Rudqvist
PublisherAcademic Press Inc.
Pages1-20
Number of pages20
ISBN (Print)9780128186770
DOIs
StatePublished - 2020

Publication series

NameMethods in Enzymology
Volume635
ISSN (Print)0076-6879
ISSN (Electronic)1557-7988

Funding

The authors thank Justin Tibbitts, Teresa Beechwood, and Meghan Lavoie for regulatory and technical assistance. This project was supported by Oregon Clinical and Translational Research Institute (OCTRI, #UL1TR000128) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), OHSU Knight Cancer Institute (P30 CA069533-17), and Grant-in-Aid for Scientific Research (17H07016) from the Japan Society for the Promotion of Science. L.M.C. acknowledges support from the NIH/NCI, Breast Cancer Research Foundation, Susan G. Komen Foundation, Stand Up To Cancer—Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant, and the Brenden-Colson Center for Pancreatic Health. The authors thank Justin Tibbitts, Teresa Beechwood, and Meghan Lavoie for regulatory and technical assistance. This project was supported by Oregon Clinical and Translational Research Institute (OCTRI, #UL1TR000128) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), OHSU Knight Cancer Institute (P30 CA069533-17), and Grant-in-Aid for Scientific Research (17H07016) from the Japan Society for the Promotion of Science. L.M.C. acknowledges support from the NIH/NCI, Breast Cancer Research Foundation, Susan G. Komen Foundation, Stand Up To Cancer?Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant, and the Brenden-Colson Center for Pancreatic Health.

FundersFunder number
Brenden-Colson Center for Pancreatic Health
Meghan Lavoie
OHSU Knight Cancer InstituteP30 CA069533-17, 17H07016
Stand Up To Cancer– Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research
Stand Up To Cancer– Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health
National Institute of Health-National Cancer Institute
Breast Cancer Research Foundation
National Center for Advancing Translational SciencesUL1TR000128
Oregon Clinical and Translational Research Institute1TR000128
Susan G. Komen for the Cure, Komen Wyoming Affiliate
Japan Society for the Promotion of Science

    Keywords

    • Cancer immunology
    • Histopathology
    • Immunohistochemistry
    • Multiplex imaging

    ASJC Scopus subject areas

    • Biochemistry
    • Molecular Biology

    Fingerprint

    Dive into the research topics of 'High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers'. Together they form a unique fingerprint.

    Cite this